Treatment with an inhibitor of 12/15-lipoxygenase, an enzyme elevated in patients with Alzheimer’s disease (AD), reverses cognitive decline and neuropathology in an AD mouse model, reports a new study. The effects were observed after the AD-like phenotype was already established in the mice, which is promising for its potential therapeutic use, as neuropathology tends to develop many years before the appearance of AD symptoms in patients.